Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Trial Profile

A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Onapristone (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 31 May 2019 Results of pooled analysis of this and NCT02052128 assessing safety of onapristone in patients with metastatic cancer, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2017 Results (n=36) of an exploratory analysis assessing outcome by plasma androgen receptor (AR) status presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top